pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

Bristol-Myers Squibb Co

updated 2mo ago

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis ; pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multip

read more…

community read0 votes

🐶 often sniffed alongside

top 8
  • drugOPDIVO12 co-mentions · 6 sources
  • drugOPDIVO QVANTIG12 co-mentions · 6 sources
  • drugnivolumab12 co-mentions · 6 sources
  • tagApproval10 co-mentions · 5 sources
  • tagOncology9 co-mentions · 1 sources
  • drug(hyaluronidase (recombinant, human) + nivolumab)5 co-mentions · 5 sources
  • tagNSCLC2 co-mentions · 1 sources
  • tagGlioblastoma2 co-mentions · 1 sources
pipeline
47
marketed
20
phase 3
8
catalysts ytd
4
approvals ytd
3
recalls ytd
0

Pipeline(47)

view full pipeline →
pipeline depth47 products
Phase 1: 5Phase 2: 13Phase 3: 8Marketed: 20pre_registration: 1
5Phase 113Phase 28Phase 320Marketed1pre_registration
Marketed
(atazanavir sulfate + cobicistat)
Human Immunodeficiency Virus (HIV) Infections (AIDS)
Marketed
(hyaluronidase (recombinant, human) + nivolumab)
Adenocarcinoma Of The Gastroesophageal Junction
Marketed
(nivolumab + relatlimab)
Metastatic Melanoma
Marketed
(trospium chloride + xanomeline tartrate)
Psychosis
Marketed
Azactam
Abscess
Marketed
LENALIDOMIDE
Follicular Lymphoma
CRL4(CRBN) E3 ubiquitin ligase
Marketed
Onureg
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Marketed
Reyataz
Human Immunodeficiency Virus (HIV) Infections (AIDS)
Marketed
abatacept
Graft Versus Host Disease (GVHD)
Marketed
adagrasib
Non-Small Cell Lung Cancer
GTPase KRas
Marketed
apixaban ODT
Venous Thromboembolism
Marketed
belatacept
Kidney Transplant Rejection

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view Bristol-Myers Squibb Co jobs →

News

  • ‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
    If AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.
    biospace · 10d ago
  • Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Cancer
    Treatment with neoadjuvant T-DXd followed by THP resulted in lower RCB vs ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer.
    onclive · 3mo ago
identifiers
source
globaldata
top tags
Oncology30NSCLC12Cardiology4Colorectal Cancer4Immunology4
mentioned in
2news items
entity-linker matched
Data sources
openFDA
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?